Winship study published in The Lancet shows increased failure-free survival in prostate cancer
Treatment guided by molecular imaging technology invented and developed by researchers at Winship Cancer Institute of Emory University shows improved disease-free survival rates for men who have undergone surgical removal of their prostate, according to findings published in the medical journal The Lancet. The randomized trial enrolled 165 patients whose cancer recurred after having their prostates removed. One group received radiation therapy using conventional imaging while the other received treatment using imaging with the fluciclovine PET radiotracer. The study found that 75.5 percent of those whose treatment integrated fluciclovine PET were disease-free after three years, compared to 63 percent for those where only conventional imaging techniques were used to plan treatment. The increased failure-free survival rate persisted after four years of follow up.